Crinetics reported Q4 FY2025 total revenue of USD 6.2 million, including USD 5.4 million in Palsonify net product revenue from its U.S. launch. Q4 cost of product revenue was USD 1.1 million, R&D expenses were USD 85.1 million, SG&A expenses were USD 53.7 million, and net loss was USD 122.8 million. For FY2025, Crinetics posted total revenue of USD 7.7 million, cost of product revenue of USD 1.1 million, R&D expenses of USD 332.1 million, SG&A expenses of USD 191.3 million, and net loss of USD 465.3 million. Cash, cash equivalents, and investment securities totaled USD 1.0 billion as of Dec. 31, 2025; the company said it completed a Jan. 8, 2026 equity offering generating approximately USD 380.0 million in net proceeds, bringing cash, cash equivalents, and investment securities to about USD 1.4 billion immediately after the offering. Business updates included FDA approval (Sept. 25, 2025) and Q4 U.S. launch of Palsonify for acromegaly, with over 200 enrollment forms by end-December and more than 125 unique HCP prescribers in Q4. Crinetics also said the EMA’s CHMP adopted a positive opinion recommending marketing authorization for Palsonify in acromegaly, and it expects to initiate a seamless Phase 2/3 EQUILIBRIUM study of atumelnant in ACTH-dependent Cushing’s syndrome in H1 2026, with first patient enrollment expected in H1 2026. The company highlighted initiation of three pivotal trials (CAREFNDR Phase 3 for paltusotine in carcinoid syndrome; CALM-CAH Phase 3 and BALANCE-CAH Phase 2/3 for atumelnant in CAH) and the start of the BRAVESST2 Phase 1/2 trial of CRN09682 in SST2-expressing tumors; it also reported Phase 2 open-label atumelnant data in CAH showing 88% of Cohort 4 participants reduced glucocorticoid doses to physiologic replacement levels by week 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602261605PRIMZONEFULLFEED9662505) on February 26, 2026, and is solely responsible for the information contained therein.